Representative Julie Johnson (D-Texas) recently sold shares of Moderna, Inc. NASDAQ: MRNA. In a filing disclosed on February 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Moderna stock on January 15th. The trade occurred in the Representative's "MERRILL LYNCH TAX EFFICIENT CORE" account.
Representative Julie Johnson also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of Dell Technologies NYSE: DELL on 1/28/2025.
- Sold $1,001 - $15,000 in shares of PepsiCo NASDAQ: PEP on 1/28/2025.
- Sold $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 1/28/2025.
- Sold $1,001 - $15,000 in shares of ALLETE NYSE: ALE on 1/28/2025.
- Sold $1,001 - $15,000 in shares of PPG Industries NYSE: PPG on 1/27/2025.
- Purchased $1,001 - $15,000 in shares of Progressive NYSE: PGR on 1/24/2025.
- Purchased $1,001 - $15,000 in shares of The Goldman Sachs Group NYSE: GS on 1/24/2025.
- Sold $1,001 - $15,000 in shares of Chubb NYSE: CB on 1/24/2025.
- Sold $1,001 - $15,000 in shares of Morgan Stanley NYSE: MS on 1/24/2025.
- Purchased $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 1/17/2025.
Moderna Stock Up 8.3 %
MRNA stock traded up $2.73 during trading on Tuesday, reaching $35.72. 18,950,644 shares of the stock were exchanged, compared to its average volume of 13,056,006. The firm's 50 day moving average is $38.61 and its 200 day moving average is $53.82. Moderna, Inc. has a twelve month low of $29.25 and a twelve month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The firm has a market cap of $13.75 billion, a P/E ratio of -6.14 and a beta of 1.59.
Insider Transactions at Moderna
In other news, insider Shannon Thyme Klinger sold 1,418 shares of the firm's stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now directly owns 19,717 shares of the company's stock, valued at $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 2,664 shares of company stock valued at $115,210 over the last three months. Company insiders own 15.70% of the company's stock.
Hedge Funds Weigh In On Moderna
Several institutional investors and hedge funds have recently bought and sold shares of MRNA. Norges Bank bought a new position in Moderna during the fourth quarter valued at $163,833,000. Voloridge Investment Management LLC grew its holdings in Moderna by 335.6% during the fourth quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock valued at $107,727,000 after purchasing an additional 1,996,003 shares during the period. State Street Corp grew its holdings in Moderna by 12.1% during the third quarter. State Street Corp now owns 16,847,212 shares of the company's stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares during the period. FMR LLC grew its holdings in Moderna by 7.4% during the fourth quarter. FMR LLC now owns 18,664,634 shares of the company's stock valued at $776,075,000 after purchasing an additional 1,282,469 shares during the period. Finally, Pictet Asset Management Holding SA grew its holdings in Moderna by 170.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company's stock valued at $73,447,000 after purchasing an additional 1,113,455 shares during the period. 75.33% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
A number of research analysts recently weighed in on the company. Morgan Stanley dropped their price target on Moderna from $70.00 to $38.00 and set an "equal weight" rating on the stock in a research note on Wednesday, January 15th. Argus downgraded Moderna from a "buy" rating to a "hold" rating in a research note on Wednesday, December 18th. UBS Group lowered their price objective on Moderna from $108.00 to $96.00 and set a "buy" rating for the company in a research note on Wednesday, January 8th. JPMorgan Chase & Co. lowered their price objective on Moderna from $59.00 to $45.00 and set an "underweight" rating for the company in a research note on Tuesday, November 26th. Finally, Bank of America lowered their price objective on Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a research note on Tuesday, February 11th. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $61.58.
Check Out Our Latest Report on Moderna
About Representative Johnson
Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas' 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.
Johnson (Democratic Party) ran for election to the U.S. House to represent Texas' 32nd Congressional District. She won in the general election on November 5, 2024.
Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson's career experience includes working as an attorney.
Moderna Company Profile
(
Get Free Report)
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Featured Articles
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
